Profound but Dysfunctional Lymphangiogenesis via Vascular Endothelial Growth Factor Ligands from CD11b+ Macrophages in Advanced Ovarian Cancer
Open Access
- 15 February 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (4) , 1100-1109
- https://doi.org/10.1158/0008-5472.can-07-2572
Abstract
Severe ascites is a hallmark of advanced ovarian cancer (OVCA), yet the underlying mechanism that creates an imbalance between peritoneal vascular leakage and lymphatic drainage is unknown. Here, we identified and characterized peritoneal lymphatic vessels in OVCA mice, a model generated by implantation of human OVCA cells into athymic nude mice. The OVCA mice displayed substantial lymphangiogenesis and lymphatic remodeling, massive infiltration of CD11b+/LYVE-1+ macrophages and disseminated carcinomatosis in the mesentery and diaphragm, and progressive chylous ascites formation. Functional assays indicated that the abnormally abundant lymphatic vessels in the diaphragm were not conductive in peritoneal fluid drainage. Moreover, lipid absorbed from the gut leaked out from the aberrant mesenteric lymphatic vessels. Our results indicate that vascular endothelial growth factor (VEGF)-C, VEGF-D, and VEGF-A from CD11b+ macrophages are responsible for producing OVCA-induced dysfunctional lymphangiogenesis, although other cell types contribute to the increased ascites formation. Accordingly, the combined blockade of VEGF-C/D and VEGF-A signaling with soluble VEGF receptor-3 and VEGF-Trap, respectively, markedly inhibited chylous ascites formation. These findings provide additional therapeutic targets to ameliorate chylous ascites formation in patients with advanced OVCA. [Cancer Res 2008;68(4):1100–9]Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2006
- Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approachBritish Journal of Cancer, 2006
- Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinomaCancer, 2006
- Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epitheliumMolecular Cancer Therapeutics, 2006
- Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer ModelClinical Cancer Research, 2005
- Development of the lymphatic vascular system: A mystery unravelsDevelopmental Dynamics, 2004
- Role of lymphangiogenic factors in tumor metastasisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodiaThe Journal of cell biology, 2003
- The Lymphatic Vessels and the So-Called “Lymphatic Stomata” of the Diaphragm: A Morphologic Ultrastructural and Three-Dimensional StudyMicrovascular Research, 1999